Our Pricing

UK's Lowest Price Weight Loss Injections - Reviews & Deals

Finding weight loss injections UK lowest price options requires comparing licensed treatments from registered pharmacies. At Cured Pharmacy, we offer transparent upfront pricing on Mounjaro (from £135.00), Wegovy (from £135.00), and Saxenda (from £135.00), with free clinical consultations completed in under 3 minutes by our UK-registered prescribers.

How Weight Loss Injections Work: Clinical Evidence

Weight loss injections licensed in the UK belong to a class called GLP-1 receptor agonists, which mimic natural hormones that regulate appetite and blood sugar control. Mounjaro (tirzepatide) represents the latest advancement as the first dual GIP/GLP-1 receptor agonist, activating two complementary pathways rather than one [1].

In the SURPASS-3 clinical trial, participants using the highest tirzepatide dose achieved an average 22.5% body weight reduction over 72 weeks, compared to 6.7% with placebo [1]. The STEP trials demonstrated semaglutide (Wegovy) produced average weight loss of 14.9% over 68 weeks [2]. These medications work by reducing appetite, slowing gastric emptying, and improving insulin sensitivity—effects that persist only while treatment continues.

All injectable weight loss treatments available through Cured Pharmacy are MHRA-licensed and require clinical assessment by a UK prescriber before dispensing. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures every prescription meets strict regulatory standards for patient safety.

Mounjaro (Tirzepatide): Dual-Action Weight Loss Injection

Mounjaro contains tirzepatide, which uniquely activates both GIP and GLP-1 receptors—two natural incretin hormones involved in metabolic regulation. This dual mechanism has demonstrated superior weight reduction outcomes compared to single-pathway GLP-1 treatments in head-to-head trials [3].

Administered once weekly via pre-filled KwikPen injector, Mounjaro follows a gradual dose escalation schedule starting at 2.5mg and increasing every 4 weeks based on tolerability and clinical response. The maintenance dose typically ranges from 5mg to 15mg weekly, determined by your prescriber during ongoing assessment.

Common side effects include nausea, diarrhoea, and reduced appetite, which usually diminish after the first few weeks as your body adjusts [1]. Clinical trials showed these effects were generally mild to moderate in severity and led to treatment discontinuation in fewer than 7% of participants.

Who Can Use Mounjaro?

Mounjaro is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or sleep apnoea. Your UK prescriber will assess your medical history, current medications, and contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 before approving treatment.

Wegovy (Semaglutide): Established GLP-1 Treatment

Wegovy contains semaglutide, a GLP-1 receptor agonist that has been extensively studied in the STEP clinical trial programme involving over 4,500 participants. The STEP 1 trial demonstrated average weight loss of 14.9% at 68 weeks versus 2.4% with placebo, with 86.4% of participants achieving at least 5% weight reduction [2].

Delivered via once-weekly subcutaneous injection, Wegovy follows a dose escalation protocol starting at 0.25mg and increasing monthly to a maintenance dose of 2.4mg. This gradual titration helps minimise gastrointestinal side effects, which are the most commonly reported adverse events.

Wegovy has been available in the UK since 2023 and benefits from extensive real-world safety data. It's particularly suitable for patients who prefer a well-established treatment option with comprehensive clinical evidence supporting long-term use.

Saxenda (Liraglutide): Daily Injection Alternative

Saxenda contains liraglutide, an earlier-generation GLP-1 receptor agonist administered via daily subcutaneous injection rather than weekly. While this requires more frequent dosing, the daily regimen allows for finer dose adjustments and may suit patients who prefer gradual metabolic changes.

Clinical trials showed liraglutide 3.0mg daily produced average weight loss of 8% over 56 weeks, with 63.2% of participants achieving at least 5% weight reduction [4]. Though numerically lower than newer weekly injections, Saxenda remains a valuable option for patients who don't tolerate higher-potency alternatives or prefer daily administration.

The starting dose of 0.6mg increases weekly by 0.6mg increments until reaching the maintenance dose of 3.0mg daily. This gradual escalation helps manage gastrointestinal side effects, which typically resolve within the first month of treatment.

Saxenda vs Weekly Injections

Choosing between daily Saxenda and weekly options like Mounjaro or Wegovy depends on individual preferences, tolerability, and clinical response. Your UK prescriber will consider factors including your previous medication experience, lifestyle requirements, and budget when recommending the most appropriate treatment during your consultation.

Weight Loss Injections UK Lowest Price Comparison

Pricing transparency remains inconsistent across UK online pharmacies, with many requiring consultation completion before revealing costs. At Cured Pharmacy, we display upfront pricing for all weight loss treatments, ensuring you make informed decisions before starting your clinical assessment.

Our pricing structure reflects genuine UK-licensed medications dispensed by our GPhC-registered pharmacy (9012511), with no hidden consultation fees or subscription requirements. The prices shown represent the lowest guaranteed rates in the UK market, verified against competitor offerings monthly.

All prescription weight loss injections require clinical assessment by a UK prescriber regardless of where you purchase them. Our free online consultation takes under 3 minutes and connects you with experienced clinicians who specialise in weight management prescribing. If approved, your medication ships in 100% discreet packaging with next-day delivery options available.

Oral Weight Loss Treatments: Orlistat and Alternatives

For patients who prefer non-injectable options, orlistat-based treatments offer an alternative mechanism of action. Orlistat works by inhibiting pancreatic lipase, preventing approximately 30% of dietary fat absorption in the intestines [5]. This leads to modest weight loss when combined with a reduced-calorie diet.

Available as prescription-strength Xenical (120mg) or lower-dose Alli and Orlos (60mg), orlistat requires three-times-daily administration with meals containing fat. Clinical trials demonstrated average weight loss of 2.9kg more than diet alone over 12 months, with best results in patients who maintain dietary fat intake below 30% of total calories [5].

Common side effects include oily stools, flatulence, and faecal urgency—effects directly related to unabsorbed fat passing through the digestive system. These can be managed by adhering to a lower-fat diet. Orlistat suits patients seeking non-systemic treatment without the injection requirement of GLP-1 medications.

Choosing Between Injections and Oral Treatments

Injectable GLP-1 treatments typically produce greater weight loss than orlistat but require weekly or daily injections and carry different side effect profiles. Your UK prescriber will assess your BMI, medical history, previous weight loss attempts, and personal preferences to recommend the most suitable option during your consultation. Many patients try orlistat first before progressing to injectable treatments if additional support is needed.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary changes, and physical activity levels. Past clinical trial results do not guarantee individual outcomes.